1. Ministry of Health and Welfare (KR). Coronavirus disease-19, Republic of Korea. Updated 2021. Accessed March 12, 2021.
http://ncov.mohw.go.kr.
2. Kim SW, Lee KS, Kim K, Lee JJ, Kim JY. Daegu Medical Association. A brief telephone severity scoring system and therapeutic living centers solved acute hospital-bed shortage during the COVID-19 outbreak in Daegu, Korea. J Korean Med Sci. 2020; 35(15):e152. PMID:
32301298.
Article
3. Ko JH, Lee JY, Kim HA, Kang SJ, Baek JY, Park SJ, et al. Serologic evaluation of healthcare workers caring for COVID-19 patients in the Republic of Korea. Front Microbiol. 2020; 11:587613. PMID:
33329460.
Article
5. Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. J Hosp Infect. 2021; 108:120–134. PMID:
33212126.
Article
6. Lee SM, Kim IS, Lim S, Lee SJ, Kim WJ, Shin KH, et al. Comparison of serologic response of hospitalized COVID-19 patients using 8 immunoassays. J Korean Med Sci. 2021; 36(9):e64. PMID:
33686810.
Article
7. Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui LP, Johnston JC, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020; 370:m2516. PMID:
32611558.
Article
8. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020; 370(6521):1227–1230. PMID:
33115920.
Article
9. Song SK, Lee DH, Nam JH, Kim KT, Do JS, Kang DW, et al. IgG seroprevalence of COVID-19 among individuals without a history of the coronavirus disease infection in Daegu, Korea. J Korean Med Sci. 2020; 35(29):e269. PMID:
32715672.
Article
10. Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun. 2021; 12(1):844. PMID:
33558507.
Article
11. Choe PG, Kim KH, Kang CK, Suh HJ, Kang E, Lee SY, et al. Antibody responses 8 months after asymptomatic or mild SARS-CoV-2 infection. Emerg Infect Dis. 2021; 27(3):928–931. PMID:
33350923.
Article
12. Park Y, Hong KH, Lee SK, Hyun J, Oh EJ, Lee J, et al. Performance comparison of five SARS-CoV-2 antibody assays for seroprevalence studies. Ann Lab Med. 2022; 42(1):71–78. PMID:
34374351.
Article